目次

Table of Content

1. Introduction To Human Leukocyte Antigen (HLA) Targeted Therapy
1.1 Overview
1.2 History, Emergence and Development

2. Human Leukocyte Antigen (HLA) System Overview
2.1 HLA Structure and Function
2.2 Role Of HLA In Immune Response
2.3 Relevance To Targeted Therapies

3. Therapeutic Indications For Human Leukocyte Antigen (HLA) Targeted Therapy
3.1 Cancer
3.1.1 Solid Tumors
3.1.2 Hematologic Cancers
3.2 Organ Transplantation
3.3 Infectious Diseases
3.4 Autoimmune Diseases
3.5 Other Indications

4. Human Leukocyte Antigen (HLA) Targeted Therapy Approaches
4.1 Antibody Based Therapies
4.2 Cell Based Therapies
4.3 Gene Editing and Gene Therapy
4.4 Small Molecule Inhibitors
4.5 Peptide Based Therapies
4.6 Other Novel Approaches

5. Human Leukocyte Antigen (HLA) Genomics and Precision Medicine
5.1 HLA Typing and Screening
5.2 Personalized Medicine and Biomarker Discovery
5.3 Companion Diagnostics For HLA-Targeted Therapy

6. Global Human Leukocyte Antigen (HLA) Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Phase

7. Global Human Leukocyte Antigen (HLA) Targeted Therapies Clinical Trials By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III

8. Global Human Leukocyte Antigen (HLA) Market Analysis
8.1 Current Market Scenario
8.2 Future Market Opportunities

9. Global Human Leukocyte Antigen (HLA) Market Dynamics
9.1 Drivers and Opportunities
9.2 Challenges and Solutions

10. Competitive Landscape
10.1 BlueSphere Bio
10.2 Diamyd Medical
10.3 Grey Wolf Therapeutics
10.4 IMBiologics
10.5 Invectys
10.6 Quell Therapeutics
10.7 Rheumagen
10.8 Sangamo Therapeutics
10.9 Tizona Therapeutics
10.10 TScan Therapeutics

List of Figures & Tables
Figure 1-1: Human Leukocyte Antigen (HLA) System and Immune Activation
Figure 1-2: Managing Risks In HLA Targeted Therapy
Figure 1-3: Evolution Of HLA Research and Therapies
Figure 1-4: Development Of HLA Targeted Therapies
Figure 2-1: HLA System and Its Role In Immune Response
Figure 2-2: HLA Classes I, II, and III
Figure 2-3: Antigen Presentation via HLA Class I Molecules
Figure 2-4: Antigen Presentation via HLA Class I Molecules
Figure 2-5: HLA Polymorphism
Figure 2-6: HLA - Key Themes By Indication
Figure 2-7: HLA In Personalized Medicine
Figure 3-1: HLA Targeted Therapy To Enhance Cancer Immunity
Figure 3-2: SCOPE Phase 2 (NCT04079166) Study - Initiation and Completion Year
Figure 3-3: DENALI-1 Phase 1/2 (NCT06682793) Study - Initiation and Completion Year
Figure 3-4: SOB100-CL-Proto-01 Phase 1 (NCT07219940) Study - Initiation and Completion Year
Figure 3-5: AFNT-211 Phase 1 (NCT06105021) Study - Initiation and Completion Year
Figure 3-6: TSCAN-001 Phase 1 (NCT05473910) Study - Initiation and Completion Year
Figure 3-7: BSB1001-CL-101 Phase 1/2 (NCT06704152) Study - Initiation and Completion Year
Figure 3-8: HLA Targeted Transplant Therapies - Treg Gene Editing
Figure 3-9: HLA Sensitization In Transplantation
Figure 3-10: QEL-001-CLN-01 Phase 1/2 (NCT05234190) Study - Initiation and Completion Year
Figure 3-11: AOTCRI-102 Phase 1/2 (NCT07053488) Study - Initiation and Completion Year
Figure 3-12: HLA and Immune Evasion By Microbes
Figure 3-13: Modulating HLA For Autoimmune Disease Treatment
Figure 3-14: HLA Modulation In Immune Diseases
Figure 4-1: HLA Targeting Antibody Mechanisms
Figure 4-2: HLA Targeted Cell Therapies - Mechanisms and Applications
Figure 4-3: Off-the-Shelf and Universal HLA Directed Cell Therapies
Figure 4-4: Peptide Based HLA Targeted Therapy - Mechanism
Figure 4-5: Peptide Based HLA Therapy - Benefits
Figure 4-6: Novel HLA Targeted Therapy Platforms
Figure 5-1: HLA Typing -Technological Evolution
Figure 5-2: Challenges In HLA Typing and Clinical Integration
Figure 5-3: HLA - Role In Personalized Medicine
Figure 5-4: Immunopeptidomics - Role In Personalized Therapy
Figure 5-5: Companion Diagnostics Workflow
Figure 6-1: Global - Number Of Human Leukocyte Antigen (HLA) In Clinical Trials By Company, 2025 -2026
Figure 6-2: Global - Number Of Human Leukocyte Antigen (HLA) In Clinical Trials By Country, 2025 -2026
Figure 6-3: Global - Number Of Human Leukocyte Antigen (HLA) In Clinical Trials By Indication, 2025 -2026
Figure 6-4: Global - Number Of Human Leukocyte Antigen (HLA) Targeting Therapies In Clinical Trials By Phase, 2025 -2026
Figure 8-1: Global Human Leukocyte Antigen (HLA) Market - Future Opportunities
Figure 9-1: Global Human Leukocyte Antigen (HLA) Market - Drivers and Opportunities
Figure 9-2: Global Human Leukocyte Antigen (HLA) Market - Challenges and Solutions
Table 2-1: Comparison Between HLA Class I and Class II Antigen Presentation
Table 2-2: HLA Based Therapies - Comparison In Different Areas
Table 4-1: HLA Targeted Cell Therapy - Techniques For Enhancing Performance
Table 5-1: HLA Typing Timeline